Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06916819

Food Challenge at Home or in Medical Practice - the FoodCHOMP Study

This is a pilot, multi-centre, randomised clinical trial evaluating the safety and feasibility of a home-based oral food challenge in adults with low-risk food allergy labels. Eligible participants are aged 18 years or older and have a self-reported food allergy with negative skin prick testing to the implicated food. Participants will be randomised to either a home-based or standard in-clinic food challenge. The primary aim is to determine the safety of home challenges, measured by the rate of immune-mediated adverse events. Secondary aims include feasibility of recruitment and delivery, protocol adherence, quality of life, and food reintroduction outcomes.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Food Allergies Food Hypersensitivity Hypersensitivity Hypersensitivity, Immediate Immune System Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Austin Health, Melbourne, Victoria, Australia

Loading trial locations.

About this study

Food allergies are highly prevalent and contribute to significant patient anxiety and healthcare utilisation. Many individuals carry food allergy labels without confirmation through diagnostic food challenge, resulting in unnecessary food avoidance. In-clinic food challenges are the current standard for confirming tolerance but are resource-intensive and often delayed. This study evaluates whether selected low-risk adults can safely complete a structured oral food challenge at home.

This is a pilot, multi-centre, randomised controlled trial conducted at two tertiary allergy centres in Victoria, Australia (Austin Health and Royal Melbourne Hospital). Adults referred with a reported food allergy will undergo clinical assessment and skin prick testing. Those with negative skin testing (<3mm wheal) to the implicated food and meeting other eligibility criteria will be randomised 1:1 to either:

  • Intervention: Home-based oral food challenge over five days, beginning with a single supervised dose in-clinic and followed by four incremental doses at home with daily clinical follow-up.
  • Control: Standard in-clinic oral food challenge using a protocol derived from PRACTALL and ASCIA guidelines.

The primary outcome is the proportion of participants experiencing an immune-mediated adverse event during food challenge. Secondary outcomes include feasibility metrics (eligibility, recruitment, delivery), non-immune mediated adverse events, protocol adherence, quality of life (measured by FAQLQ-12), time to challenge, and real-world food reintroduction.

The study will enrol 120 participants (60 per arm). Outcomes will inform the design of a future non-inferiority trial and may support integration of home challenges into routine practice for selected patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Negative (<3mm) fresh or extract skin testing to the food implicated within their allergy label
  • Aged greater than 18 years

Exclusion criteria

  • Evidence of prior sensitisation to challenge food 0 Defined as previously positive skin testing or allergen specific IgEs if available
  • Pregnancy
  • Patients with poorly controlled asthma - defined as an ACQ5 scores >1 at the time of enrolment
  • Patients with a history of food reactions that is not-consistent with an IgE mediated process; i.e. exclusively gastrointestinal symptoms, FPIES
  • Patients with a clear history of food-dependent exercise induced anaphylaxis
  • Patients on a concurrent medication which may influence the outcome of the challenge;
  • Antihistamine therapy; Patients receiving more than stress dose steroids (i.e. > 50mg QID hydrocortisone [or steroid equivalent]); Omalizumab
  • Any other illness that, in the investigator's judgement, will substantially increase the risk associated with subject's participation in this study

Treatment and study plan

Home-Based Food Challenge

Diagnostic Test

Participants randomised to the intervention arm will undertake a structured home-based oral food challenge over five consecutive days. This begins with an initial supervised dose administered in clinic under medical observation (60-minute monitoring period). Participants will then self-administer increasing doses of the implicated food at home each subsequent day using a standardised protocol adapted from PRACTALL and ASCIA guidelines. Dose intervals are 24 hours to reduce risk of cumulative reactions. Participants are provided with written instructions, emergency action plans, and have daily phone follow-up with allergy nursing staff during the challenge. The challenge food is selected by the participant from their eligible food allergy labels.

In-Clinic Food Challenge

Diagnostic Test

Standard of care - Participants randomised to the control arm will undergo a standard in-clinic oral food challenge conducted under direct medical supervision. The protocol used is derived from the PRACTALL consensus and ASCIA position statements and involves administration of increasing doses of the implicated food at 20-30 minute intervals over a 2-3 hour period. Observation continues for 1-2 hours post final dose. The challenge is performed in a hospital outpatient clinic equipped for anaphylaxis management. The food challenged is selected by the participant from their eligible food allergy labels.

Primary outcomes

  1. Proportion of participants experiencing immune-mediated adverse events during food challenge

    Time frame: During the food challenge period (Days 1-5 post-randomisation)

    Immune-mediated adverse events are defined as clinical symptoms consistent with IgE-mediated food allergy occurring during the food challenge, including but not limited to: urticaria, angioedema, vomiting, diarrhoea, or respiratory compromise (e.g., wheezing, cough, stridor). Events will be recorded according to a standardised adverse event form. For home challenges, participants will self-report symptoms daily and receive follow-up via nursing staff. In-clinic events will be recorded by supervising clinicians.

Secondary outcomes

  1. Proportion of screened patients who are eligible for randomisation (Eligibility-to-screened ratio)

    Time frame: Baseline visit

    Feasibility metric defined as the proportion of patients referred to outpatient allergy clinic who meet the trial eligibility criteria (including negative skin prick testing to the implicated food and absence of exclusion criteria).

  2. Proportion of eligible patients who consent to participate (Recruitment-to-eligibility ratio)

    Time frame: At consent discussion (baseline visit)

    Feasibility of recruitment measured as the proportion of eligible patients who provide written informed consent to participate in the trial.

  3. Proportion of randomised participants who receive the allocated intervention (Intervention-to-recruitment ratio)

    Time frame: Day 1 to Day 5 (intervention delivery period)

    Defined as the proportion of randomised participants who complete their allocated food challenge (home or in-clinic) in accordance with protocol.

  4. Proportion of participants experiencing non-immune mediated adverse events

    Time frame: Day 1 to Day 5 (challenge period)

    Non-immune mediated events include those not consistent with IgE-mediated allergy and not meeting serious adverse event criteria. Examples: taste aversion, food refusal, procedural anxiety. Events will be recorded via self-report or in-clinic observation.

  5. Proportion of participants with severe adverse reactions (anaphylaxis or death)

    Time frame: Day 1 to Day 5 (challenge period)

    Serious adverse events are defined per ICH-GCP and include anaphylaxis (as per ASCIA criteria) or death.

  6. Difference in proportion of participants tolerant to challenge food

    Time frame: At completion of challenge (Day 5)

    Defined as the proportion of participants in each arm who successfully consume the full challenge dose without meeting stopping criteria or experiencing adverse events. Tolerance is determined according to protocol-defined thresholds.

  7. Change in Food Allergy Quality of Life (FAQLQ-12) score from baseline

    Time frame: Baseline and 6 months post-randomisation

    Measured using the FAQLQ-12, a validated 12-item quality of life tool for adults with food allergy. Change in score will be assessed as a continuous variable.

  8. Proportion of participants consuming the challenge food post-trial

    Time frame: At 6-month follow-up

    Defined as the proportion of participants who report active inclusion of the challenge food in their diet at least once per week following a successful challenge.

  9. Time from clinic referral to challenge completion

    Time frame: From the date of referral for food challenge to date of challenge completion or withdrawal from the study assessed up to 60 months.

    Measured in days to assess whether home-based challenge reduces diagnostic delay compared to in-clinic challenge.

    Data collected through clinic administrative records.

Sponsors and collaborators

Lead sponsor

Austin Health

Other Gov

Collaborators

  • Royal Melbourne Hospital, Australia

Registry information

Official study title

Food Challenge at Home or in Medical Practice - a Multi-center Randomized Control Trial - FoodCHOMP Study

Acronym: CHOMP

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Apr 8, 2025
Registry last updated
Apr 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.